Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Solitary plasmacytoma is an infrequent form of plasma cell dyscrasia that presents as a single mass of monoclonal plasma cells, located either extramedullary or intraosseous. In some patients, a bone marrow aspiration can detect a low monoclonal plasma cell infiltration which indicates a high risk of early progression to an overt myeloma disease. Before treatment initiation, whole body positron emission tomography–computed tomography or magnetic resonance imaging should be performed to exclude the presence of additional malignant lesions. For decades, treatment has been based on high-dose radiation, but studies exploring the potential benefit of systemic therapies for high-risk patients are urgently needed. In this review, a panel of expert European hematologists updates the recommendations on the diagnosis and management of patients with solitary plasmacytoma.

Electronic supplementary material

The online version of this article (10.1186/s13045-017-0549-1) contains supplementary material, which is available to authorized users.

Related collections

Most cited references 34

Record: found
Abstract: found
Article: found

Is Open Access

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

J van Dongen, L Lhermitte, S Böttcher … (2012)

Most consensus leukemia & lymphoma antibody panels consist of lists of markers based on expert opinions, but they have not been validated. Here we present the validated EuroFlow 8-color antibody panels for immunophenotyping of hematological malignancies. The single-tube screening panels and multi-tube classification panels fit into the EuroFlow diagnostic algorithm with entries defined by clinical and laboratory parameters. The panels were constructed in 2–7 sequential design–evaluation–redesign rounds, using novel Infinicyt software tools for multivariate data analysis. Two groups of markers are combined in each 8-color tube: (i) backbone markers to identify distinct cell populations in a sample, and (ii) markers for characterization of specific cell populations. In multi-tube panels, the backbone markers were optimally placed at the same fluorochrome position in every tube, to provide identical multidimensional localization of the target cell population(s). The characterization markers were positioned according to the diagnostic utility of the combined markers. Each proposed antibody combination was tested against reference databases of normal and malignant cells from healthy subjects and WHO-based disease entities, respectively. The EuroFlow studies resulted in validated and flexible 8-color antibody panels for multidimensional identification and characterization of normal and aberrant cells, optimally suited for immunophenotypic screening and classification of hematological malignancies.

0 comments Cited 267 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group.

Michele Cavo, Evangelos Terpos, Cristina Nanni … (2017)

The International Myeloma Working Group consensus aimed to provide recommendations for the optimal use of (18)fluorodeoxyglucose ((18)F-FDG) PET/CT in patients with multiple myeloma and other plasma cell disorders, including smouldering multiple myeloma and solitary plasmacytoma. (18)F-FDG PET/CT can be considered a valuable tool for the work-up of patients with both newly diagnosed and relapsed or refractory multiple myeloma because it assesses bone damage with relatively high sensitivity and specificity, and detects extramedullary sites of proliferating clonal plasma cells while providing important prognostic information. The use of (18)F-FDG PET/CT is mandatory to confirm a suspected diagnosis of solitary plasmacytoma, provided that whole-body MRI is unable to be performed, and to distinguish between smouldering and active multiple myeloma, if whole-body X-ray (WBXR) is negative and whole-body MRI is unavailable. Based on the ability of (18)F-FDG PET/CT to distinguish between metabolically active and inactive disease, this technique is now the preferred functional imaging modality to evaluate and to monitor the effect of therapy on myeloma-cell metabolism. Changes in FDG avidity can provide an earlier evaluation of response to therapy compared to MRI scans, and can predict outcomes, particularly for patients who are eligible to receive autologous stem-cell transplantation. (18)F-FDG PET/CT can be coupled with sensitive bone marrow-based techniques to detect minimal residual disease (MRD) inside and outside the bone marrow, helping to identify those patients who are defined as having imaging MRD negativity.

0 comments Cited 164 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Solitary plasmacytoma of bone and asymptomatic multiple myeloma.

M Dimopoulos, L Moulopoulos, Nikolaos Maniatis … (2000)

Most patients with multiple myeloma (MM) present with symptoms, have evidence of generalized disease, and require chemotherapy promptly to reduce the malignant clone. Some patients present with a local symptom from a single plasmacytoma but no myeloma elsewhere. Such patients usually become free of symptoms after local radiotherapy. In patients with MM without symptoms, the diagnosis is made on the basis of screening laboratory tests. In patients with either solitary plasmacytoma of bone or asymptomatic MM, systemic treatment should be deferred until there is evidence of disease progression.

0 comments Cited 73 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

J. Caers:

ORCID: http://orcid.org/0000-0002-3175-1195

+32 4 366 77 04 , jo.caers@chu.ulg.ac.be

B. Paiva: bpaiva@unav.es

E. Zamagni: e.zamagni@unibo.it

X. Leleu: Xavier.LELEU@chu-poitiers.fr

J. Bladé: JBLADE@clinic.cat

S. Y. Kristinsson: Sigurdur.Kristinsson@ki.se

C. Touzeau: Cyrille.TOUZEAU@chu-nantes.fr

N. Abildgaard: Niels.Abildgaard@rsyd.dk

E. Terpos: eterpos@hotmail.com

R. Heusschen: R.Heusschen@uliege.be

E. Ocio: emocio@usal.es

M. Delforge: michel.delforge@uzleuven.be

O. Sezer: orhan.sezer@gmx.com

M. Beksac: mbeksac56@gmail.com

H. Ludwig: heinz.ludwig1@extern.wienkav.at

G. Merlini: gmerlini@unipv.it

P. Moreau: philippe.moreau@chu-nantes.fr

S. Zweegman: S.Zweegman@vumc.nl

M. Engelhardt: monika.engelhardt@uniklinik-freiburg.de

L. Rosiñol: LROSINOL@clinic.cat

Journal

Journal ID (nlm-ta): J Hematol Oncol

Journal ID (iso-abbrev): J Hematol Oncol

Title: Journal of Hematology & Oncology

Publisher: BioMed Central (London )

ISSN (Electronic): 1756-8722

Publication date (Electronic): 16 January 2018

Publication date PMC-release: 16 January 2018

Publication date Collection: 2018

Volume: 11

Electronic Location Identifier: 10

Affiliations

[1 ]ISNI 0000 0000 8607 6858, GRID grid.411374.4, Department of Hematology, , CHU de Liège, ; Liège, Belgium

[2 ]Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicadas (CIMA); Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBERONC, Pamplona, Spain

[3 ]ISNI 0000 0004 1757 1758, GRID grid.6292.f, Seràgnoli Institute of Hematology, , Bologna University School of Medicine, ; Bologna, Italy

[4 ]ISNI 0000 0000 9336 4276, GRID grid.411162.1, Hopital La Miletrie, , University Hospital of Poitiers, ; Poitiers, France

[5 ]ISNI 0000 0004 1937 0247, GRID grid.5841.8, Department of Hematology, Hospital Clínic de Barcelona, , IDIBAPS, ; Barcelona, Spain

[6 ]ISNI 0000 0000 9894 0842, GRID grid.410540.4, Department of Hematology, , Landspitali National University Hospital, ; Reykjavik, Iceland

[7 ]ISNI 0000 0004 0472 0371, GRID grid.277151.7, Department of Hematology, , University Hospital Hôtel-Dieu, ; Nantes, France

[8 ]ISNI 0000 0004 0512 5013, GRID grid.7143.1, Department of Hematology, , Odense University Hospital, ; Odense, Denmark

[9 ]ISNI 0000 0001 2155 0800, GRID grid.5216.0, Department of Clinical Therapeutics, School of Medicine, , National and Kapodistrian University of Athens, ; Athens, Greece

[10 ]GRID grid.411258.b, Instituto de Investigacion Biomedica de Salamanca, Centro de Investigación del Cancer, , Hospital Universitario de Salamanca, ; Salamanca, Spain

[11 ]ISNI 0000 0004 0626 3338, GRID grid.410569.f, Department of Hematology, , University Hospital Leuven, ; Leuven, Belgium

[12 ]ISNI 0000 0001 2180 3484, GRID grid.13648.38, Department of Haematology, Oncology, and Bone Marrow Transplantation, , Universitaetsklinikum Eppendorf, ; Hamburg, Germany

[13 ]ISNI 0000000109409118, GRID grid.7256.6, Department of Hematology, , University of Ankara, ; Ankara, Turkey

[14 ]ISNI 0000 0004 0524 3028, GRID grid.417109.a, Department of Medicine I, , Wilhelminen Hospital, ; Vienna, Austria

[15 ]ISNI 0000 0004 1762 5736, GRID grid.8982.b, Department of Molecular Medicine, Amyloidosis Research and Treatment Center, Foundation ‘Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo’, , University of Pavia, ; Pavia, Italy

[16 ]ISNI 0000 0004 0435 165X, GRID grid.16872.3a, Department of Hematology, , VU University Medical Center, ; Amsterdam, the Netherlands

[17 ]ISNI 0000 0000 9428 7911, GRID grid.7708.8, Department of Hematology and Oncology, , University of Freiburg Medical Center, ; Freiburg, Germany

Author information

J. Caers http://orcid.org/0000-0002-3175-1195

Article

Publisher ID: 549

DOI: 10.1186/s13045-017-0549-1

PMC ID: 5771205

PubMed ID: 29338789

SO-VID: c5236b77-34cb-46e2-9659-91b9027fcb6d

License:

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

History

Date received : 26 October 2017

Date accepted : 26 December 2017

Funding

Funded by: FundRef http://dx.doi.org/10.13039/501100005026, Stichting Tegen Kanker;

Funded by: FundRef http://dx.doi.org/10.13039/501100002661, Fonds De La Recherche Scientifique - FNRS;

Funded by: FundRef http://dx.doi.org/10.13039/501100005972, Deutsche Krebshilfe;

Award ID: 1095969

Award ID: 111424

Funded by: FundRef http://dx.doi.org/10.13039/501100002704, Fundación Científica Asociación Española Contra el Cáncer;

Award ID: GCB120981SAN

Custom metadata

ScienceOpen disciplines: Oncology & Radiotherapy

Keywords: solitary plasmacytoma,extramedullary plasmacytoma,myeloma,plasma cell dyscrasia,pet/ct,mri,radiotherapy

Data availability:

ScienceOpen disciplines: Oncology & Radiotherapy

Keywords: solitary plasmacytoma, extramedullary plasmacytoma, myeloma, plasma cell dyscrasia, pet/ct, mri, radiotherapy

Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel

Read this article at

Abstract

Electronic supplementary material

Related collections

Karger: Oncology

Most cited references 34

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group.

Solitary plasmacytoma of bone and asymptomatic multiple myeloma.

Author and article information

Contributors

Journal

Affiliations

Author information

Article

History

Funding

Categories

Custom metadata

Comments

Comment on this article

Similar content 377

Cited by 91

Most referenced authors 1,032